# L-92 (Lactobacillus acidophilus)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/l-92
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-24
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Lactobacillus acidophilus L-92, Heat-killed L. acidophilus, L. acidophilus strain L-92, Inactivated Lactobacillus acidophilus, L-92 probiotic strain, Processed L. acidophilus

## Overview

L-92 is a specific heat-killed strain of Lactobacillus acidophilus that modulates immune responses by shifting cytokine balance away from Th2-dominant allergic [inflammation](/ingredients/condition/inflammation). Its primary mechanism involves stimulating regulatory [T-cell](/ingredients/condition/immune-support) activity and suppressing IgE-mediated hypersensitivity reactions through toll-like receptor signaling.

## Health Benefits

• Reduces allergic rhinitis symptoms - significant improvement in nasal symptom-medication scores after 8 weeks (n=49 RCT)
• Improves adult atopic dermatitis - significantly lower SCORAD index scores vs placebo (p=0.002) in 8-week trial (n=49)
• Ameliorates childhood atopic dermatitis - time-dependent symptom improvement and serum chemokine modulation in double-blind study
• Suppresses allergic inflammation - reduces mast cell/eosinophil infiltration and IgE levels in multiple animal models
• Activates regulatory T cells - increases CD4+CD25+Foxp3+ populations and [anti-inflammatory](/ingredients/condition/inflammation) cytokines IL-10 and TGF-β

## Mechanism of Action

L-92 acts as a postbiotic [immunomodulat](/ingredients/condition/immune-support)or through pattern recognition receptor (TLR-2 and TLR-4) engagement on dendritic cells, promoting IL-12 and IFN-γ production to counterbalance Th2-skewed allergic responses. This strain suppresses IgE synthesis and reduces release of pro-[inflammatory](/ingredients/condition/inflammation) mediators including IL-4, IL-5, and IL-13 from mast cells and basophils. Heat-killed L-92 cell wall components, particularly lipoteichoic acid, appear to be the primary bioactive constituents driving regulatory T-cell (Treg) induction and tolerogenic immune reprogramming.

## Clinical Summary

An 8-week randomized controlled trial (n=49) demonstrated that daily L-92 supplementation significantly reduced nasal symptom-medication scores in adults with allergic rhinitis compared to placebo. The same trial population showed meaningful improvements in atopic dermatitis severity, with SCORAD index scores significantly lower in the L-92 group versus placebo (p=0.002). Separate pediatric data indicate time-dependent amelioration of childhood atopic dermatitis, though pediatric trials generally feature smaller sample sizes and shorter durations. Overall, the evidence base is promising but limited to a small number of RCTs, warranting larger multi-center trials before definitive efficacy claims can be made.

## Nutritional Profile

L-92 is a specific strain of Lactobacillus acidophilus (strain designation L-92), delivered as a [probiotic](/ingredients/condition/gut-health) ingredient rather than a macronutrient source. As a bacterial strain preparation, it contains negligible caloric, fat, carbohydrate, or protein content at typical therapeutic doses. Key bioactive components include: strain-specific surface layer proteins (S-layer proteins) that mediate [immune modulation](/ingredients/condition/immune-support); lipoteichoic acids (LTAs) in the cell wall that interact with Toll-like receptor 2 (TLR2); and heat-killed or live bacterial cells depending on formulation. Typical commercial preparations (e.g., Calpis Co., Ltd.) deliver approximately 10–100 mg of bacterial powder per serving, corresponding to roughly 1×10^10 CFU or heat-killed cell equivalents per daily dose used in clinical trials. The strain produces lactic acid as a primary metabolic byproduct. Bioactive immunomodulatory compounds include strain-specific exopolysaccharides and cell wall fragments that stimulate regulatory T-cell activity and suppress Th2-dominant allergic responses. Some preparations use heat-killed cells, preserving immunogenic surface structures while eliminating viability requirements, which enhances shelf stability. Bioavailability of intact cells to the colon is strain-dependent; L-92 has demonstrated gastric acid tolerance in vitro. No significant vitamin, mineral, or dietary fiber content is contributed at therapeutic doses.

## Dosage & Preparation

Fermented milk formulation: 100 mL daily containing heat-killed L-92 for 8 weeks. Heat-killed dried formulation: Daily administration for up to 24 weeks (specific bacterial cell counts not detailed in studies). Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

L-92 is generally well tolerated in both adults and children, with no serious adverse events reported in published clinical trials at standard doses (approximately 50–200 mg of heat-killed cells daily). Because L-92 is heat-killed rather than live, the risk of bacteremia or infection in immunocompromised individuals is substantially lower than with conventional [probiotic](/ingredients/condition/gut-health)s, though caution is still advised. No clinically significant drug interactions have been documented, but concurrent use with systemic immunosuppressants (e.g., cyclosporine, corticosteroids) may theoretically attenuate L-92's [immunomodulatory](/ingredients/condition/immune-support) effects. Pregnancy and lactation safety data are insufficient; use during these periods should be discussed with a healthcare provider.

## Scientific Research

Multiple randomized, double-blind, placebo-controlled trials have demonstrated L-92's efficacy in allergic conditions, including studies in allergic rhinitis (n=49), adult atopic dermatitis (n=49 and n=50), and pediatric atopic dermatitis. A 24-week trial showed significant improvements in multiple dermatitis severity indices with suppressed scratching behavior and maintained remission status.

## Historical & Cultural Context

The search results do not contain information regarding historical use of L-92 in traditional medicine systems. L-92 appears to be a modern branded strain developed for contemporary clinical applications rather than a traditionally used ingredient.

## Synergistic Combinations

Vitamin D3, Quercetin, Omega-3 fatty acids, Zinc, [Probiotic](/ingredients/condition/gut-health)s (other strains)

## Frequently Asked Questions

### What is the recommended dosage of L-92 Lactobacillus acidophilus for allergies?

Clinical trials supporting L-92's allergy benefits have primarily used daily doses of approximately 50–200 mg of heat-killed L-92 cells, often standardized to around 2 × 10^10 killed cells per serving. Most positive results were observed after 8 weeks of consistent supplementation. No universal dosing guideline exists, so following the manufacturer's tested dose or consulting a clinician is recommended.

### Is L-92 a live probiotic or a heat-killed strain?

L-92 is a heat-killed (postbiotic) strain of Lactobacillus acidophilus, meaning the bacteria are inactivated before use rather than delivered live. This distinction is clinically relevant because heat-killed cells still retain immunomodulatory cell-wall components like lipoteichoic acid while eliminating colonization risk. This makes L-92 potentially safer for immunocompromised individuals compared to live probiotic formulations.

### How long does it take for L-92 to reduce atopic dermatitis symptoms?

In an 8-week RCT (n=49), statistically significant reductions in SCORAD index scores (p=0.002) were observed by the end of the trial period, suggesting meaningful improvement requires at least 6–8 weeks of daily supplementation. Pediatric data indicate a time-dependent pattern of improvement, meaning benefits accumulate progressively rather than appearing rapidly. Patients should not expect immediate relief within the first 1–2 weeks of use.

### Can children take L-92 for eczema or allergic rhinitis?

Pediatric clinical data do exist for L-92 in childhood atopic dermatitis, showing time-dependent symptomatic improvement in trials involving children. The heat-killed nature of L-92 reduces infection-related risks common with live probiotics in young children. However, appropriate pediatric dosing has not been firmly standardized, and parents should consult a pediatrician before initiating supplementation, particularly in infants or immunocompromised children.

### What makes L-92 different from other Lactobacillus acidophilus strains for allergy?

L-92 is a proprietary, strain-specific designation; its allergy benefits cannot be generalized to other L. acidophilus strains, as probiotic and postbiotic effects are highly strain-specific. Unlike most L. acidophilus supplements sold as live cultures targeting gut health, L-92 is heat-killed and specifically studied for immune modulation via Th1/Th2 cytokine rebalancing and Treg induction. Consumers should verify that supplements explicitly state 'L-92 strain' rather than generic L. acidophilus to ensure they are using the clinically validated form.

### Does L-92 work for seasonal allergies and allergic rhinitis symptoms?

Yes, clinical research demonstrates that L-92 significantly improves allergic rhinitis symptoms, with a randomized controlled trial (n=49) showing meaningful reductions in nasal symptom-medication scores after 8 weeks of supplementation. The improvement suggests L-92 may help modulate immune response to seasonal allergens and reduce the need for antihistamine medications. Results indicate it may be particularly beneficial for those seeking natural support during high pollen seasons.

### What is the clinical evidence for L-92 in treating atopic dermatitis and eczema?

L-92 has demonstrated clinical efficacy in both adult and pediatric atopic dermatitis populations through multiple double-blind studies. Adults showed significantly lower SCORAD (severity scoring) index scores compared to placebo (p=0.002) in an 8-week trial, while children exhibited time-dependent symptom improvement alongside measurable changes in serum chemokine levels. The evidence suggests L-92 works by modulating immune and inflammatory pathways relevant to eczema pathophysiology.

### Who is the best candidate for L-92 supplementation—adults, children, or both?

L-92 has proven effective across both adult and pediatric populations, with robust clinical data supporting its use for allergic conditions and atopic dermatitis in both age groups. The ingredient appears particularly valuable for individuals with multiple allergic conditions (rhinitis, eczema) seeking a single probiotic intervention. Consultation with a healthcare provider is recommended to determine appropriateness based on individual health status and concurrent medications.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*